Tag: Visanne

According to pooled clinical trial data, approximately 5.4% of women taking Visanne (dienogest) experienced breast discomfort, including breast tenderness. This makes breast tenderness a recognized and relatively common side effect for those using the medication to manage endometriosis symptoms.

Endometriosis affects approximately 10% (190 million) of reproductive-age women and girls globally. For many, dienogest has emerged as a key treatment. So, what are the benefits of dienogest in managing this chronic condition?

According to official product information, Visanne can be taken with or without food, as its effectiveness is not significantly impacted by food intake. However, some users report experiencing side effects like nausea or discomfort when they take VISANNE on an empty stomach, suggesting that personal tolerance is a key factor to consider.

Visanne, the brand name for the active ingredient dienogest, is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of endometriosis. Consequently, there is no official retail price for **Visanne cost in the US** through domestic pharmacies. However, patients may source the medication from international online pharmacies, where prices can vary widely.

According to patient information leaflets, consuming grapefruit juice while on Visanne can significantly increase the drug's levels in the bloodstream, raising the risk of side effects. To ensure your treatment is safe and effective, it's vital to know what not to eat while taking Visanne and how specific substances can interact with this medication.

According to pooled analyses of clinical trials, breast discomfort was one of the most commonly reported adverse events, occurring in less than 10% of women using dienogest for endometriosis. While often mild or moderate, this symptom is a legitimate concern and leads many patients to ask: “Does dienogest cause breast pain?”

While not experienced by everyone, several studies have reported weight gain as a potential side effect for some individuals taking dienogest. In one clinical trial comparing dienogest to leuprolide acetate, weight gain was significantly higher in the dienogest group, affecting just over 10% of participants. However, another longer-term Korean study showed a higher percentage of patients, around 24%, experienced this side effect. The potential for dienogest to cause weight gain is a documented concern for some users.

While Visanne (dienogest) is approved for treating endometriosis in Europe, Canada, Australia, and Japan, it has not been approved by the U.S. Food and Drug Administration (FDA) [1.2.1, 1.3.1]. This raises a critical question for many: why is Visanne not available in the US?

Dienogest, a fourth-generation progestin, is used worldwide for the management of endometriosis-related pain and symptoms. It has been shown to effectively reduce painful symptoms, with long-term data indicating sustained pain relief. When you take dienogest, it works to create a low-estrogen, high-progestin environment, leading to the atrophy of endometrial lesions.